Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.50 (3.529%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 44.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations

Mon, 11th May 2020 12:03

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Monday and not separately reported by Alliance News:

----------

Open Orphan PLC - pharmaceutical services - Subsidiary hVIVO enters contract with Nasdaq-listed diagnostics firm Quotient to use MosaiQ system and MosaiQ Covid-19 antibody microarray to screen for SARS-CoV-2 antibodies, which is produced when humans are infected with Covid-19.

----------

Avacta Group PLC - biotherapeutics - To ship Affimer reagents for the development of a point-of-care saliva-based Covid-19 antigen test strip by Cytiva, for CE Marking in Europe and US Food & Drug Administration approval. Will also be sent to Adeptrix, which is developing Covid-19 laboratory test to run on hospital mass spectrometers.

----------

BlueRock Diamonds PLC - diamonds - Recommences operations at Kareevlei diamond mine in Kimberley, South Africa. Expects to start operations at full capacity by the end of May, but expansion plans on hold.

----------

Chesterfield Resources PLC - mineral exploration - Plans to resume drilling operations on its Troodos West licences by mid-June, following government of Cyprus providing a detailed four-phase roadmap out of lockdown, which is spread over the next two months up until July 14.

----------

Blencowe Resources PLC - mining - Recommences key metallurgical test work on Orom-Cross graphite project in Uganda, after being on hold for six weeks since late March due to lockdown. Due to restart 59-hole diamond drilling programme, which is designed to deliver a maiden JORC resource during the middle of 2020.

----------

Phoenix Spree Deutschland Ltd - real estate - Rent collection for April at 98% compared to 99% in January. Refinances EUR16.4 million in debt acquired as part of acquisition of Brandenburg apartment complex. Will pay second dividend of 5.15 cents per share, remain confident in long-term outlook.

----------

Petro Matad Ltd - Mongolian oil explorer - Executive directors, non-executive directors and senior managers to take salary cut averaging 50%, backdated to the start of second quarter of 2020. Professional advisers to reduce its fees by up to 45%. To focus on securing Block XX exploitation licence and retaining its Block V exploitation licence.

----------

Anglo African Agriculture PLC - agriculture investment - Trading subsidiary Dynamic Intertrade remains fully operational despite South Africa lockdown, due to providing essential services as a food manufacturer. Expects revenue for six months ending October 31 to double year-on-year. Progress with Comarco transaction protracted due to general market environment.

----------

iEnergizer Ltd - media and technology services - Continues to trade effectively in lockdown imposed by government of India. Business operating at 80% to 90% efficiency to its clients. Balance sheet, net cash position and long-term customer relationships remain strong.

----------

Cake Box Holdings PLC - cakes retailer - Following initial trial of limited number of stores operating Click & Collect service and delivery in partnership, now has 79 franchise stores open, offering a limited menu of products. Expects to have full high street estate open by early June.

----------

Midwich Group PLC - audio-visual distributor - Delivered strong performance in 2019, with growth in revenue and rise in profit. Challenging trading conditions over the past two months, expected to continue until lockdown conditions in Europe and North America are "significantly eased".

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2023 09:43

Avacta presents pre-clinical data for anti-cancer candidate

(Sharecast News) - Life science company Avacta Group announced the presentation of pre-clinical data for its novel 'preCISION' proteasome inhibitor AVA3996 on Monday.

Read more
6 Apr 2023 12:14

Avacta opens first two clinical investigator sites in US for AVA6000

(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application.

Read more
6 Apr 2023 10:09

Avacta opens first US clinical investigator sites

(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.

Read more
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.